Novartis AG
Change company Symbol lookup
Select an option...
NVS Novartis AG
INVH Invitation Homes Inc
OII Oceaneering International Inc
SINO Sino-Global Shipping America Ltd
MLM Martin Marietta Materials Inc
KO Coca-Cola Co
VICI VICI Properties Inc
PLT Plantronics Inc
THG Hanover Insurance Group Inc
USB U.S. Bancorp
Go

Health Care : Pharmaceuticals | Large Cap Value
Based in Switzerland
Company profile

Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company's segments include Innovative Medicines, Sandoz, Alcon and Corporate activities. Innovative Medicines researches, develops, manufactures, distributes and sells patented prescription medicines to develop health outcomes for patients and healthcare providers. Sandoz develops, manufactures, distributes and sells prescription medicines, as well as pharmaceutical active substances that are not protected by valid and enforceable third-party patents. Alcon researches, develops, manufactures, distributes and sells eye care products. Alcon is a provider of eye care with product offerings in eye care devices and vision care. The Company's range of products includes pharmaceuticals and oncology medicines, generic and biosimilar medicines, and eye care devices.

This security is an American depositary receipt
ADR Fees
American Depositary Receipt (ADR) Fee

ADR fees charged by custodial banks normally average from 1 to 3 cents per share. Other country fees might apply. To read more, see the Exception Fees tab at Brokerage Fees

Postmarket

Last Trade
Delayed
$78.10
0.02 (0.03%)
Bid
--
Ask
--
B/A Size
--

Market Hours

Closing Price
$78.08
Day's Change
0.01 (0.01%)
Bid
--
Ask
--
B/A Size
--
Day's High
78.08
Day's Low
77.04
Volume
(Below Average)
Volume:
1,467,770

10-day average volume:
1,743,536
1,467,770

Display:

Providers:

UpdateCancel
6 providers
Today's News, October 30, 2020
Eyewear Market Size is Worth USD 178.95 Billion and Exhibit a CAGR of 5.7%; Gain from Increasing Prevalence of Ocular Disorders Worldwide: Fortune Business Insights reports

The global eyewear market size is anticipated to expand owing to the increasing awareness about ocular diseases, coupled with the rise in prevalence of vision abnormality. A report on eyewear market by Fortune Business Insights. According to the...(Globe Newswire)

Smart Inhalers Market Worth USD 445.40 Million and Exhibit 41.1% CAGR till 2027; Increasing Prevalence of Asthma & COPD to Boost Growth: Fortune Business Insights(TM)

The global smart inhalers market size is set to gain impetus from the rising utilization of digital technology in the field of healthcare devices. It is aiding in increasing the efficiency of drug delivery devices and is, in turn, speeding up the...(Globe Newswire)

Dr. Ellen R. Strahlman Elected to Altria's Board of Directors

Altria Group, Inc. (Altria) (NYSE:MO) announces that Dr. Ellen R. Strahlman will join its Board of Directors on November 2, 2020. Dr. Strahlman served as Executive Vice President, Research & Development and Chief Medical Officer of Becton...(BusinessWire)

Novartis expands Kymriah(R) manufacturing footprint with first-ever approved site for commercial CAR-T cell therapy manufacturing in Asia

- Foundation for Biomedical Research and Innovation (FBRI) in Kobe, Japan becomes first CAR-T cell therapy commercial manufacturing site in Asia - Novartis global CAR-T manufacturing footprint now spans four continents, bringing Kymriah closer to...(Thomson Reuters ONE)

Yesterday's News, October 29, 2020
Novartis Acquires Vedere Bio, a Novel Optogenetics AAV Gene Therapy Company

Vedere Bio, Inc. (Vedere Bio), a stealth-stage company focused on advancing photoreceptor-protein-based optogenetic therapies that are delivered to the retina intravitreally to restore functional vision, announced today that it has been acquired by...(PR Newswire)

October 28, 2020
Pancreatic Cancer Action Network Announces New Industry Partner To Accelerate New Therapies To Market Through Precision Promise Clinical Trial Platform

Patient advocacy organization, Pancreatic Cancer Action Network (PanCAN) has announced plans to collaborate with the global healthcare company, Novartis, to accelerate pancreatic cancer therapies to market through PanCAN's adaptive clinical trial...(PR Newswire)

XOMA Earns $25 Million Milestone Payment as Anti-TGFB Antibody Enters Phase 2 Clinical Study in Metastatic Pancreatic Cancer

XOMA Corporation (Nasdaq: XOMA) announced today NIS793, an anti-TGFB monoclonal antibody licensed from XOMA, has advanced to the Phase 2 development stage, triggering a $25 million milestone payment from Novartis. The Phase 2 trial (NCT04390763)...(Globe Newswire)

Molecular Partners Announces Collaboration With Novartis to Develop Two DARPin(R) Therapies Designed for Potential Use Against COVID-19

Novartis has been granted an option to in-license global rights of MP0420 and MP0423 - multi-targeted direct-acting antiviral therapeutic candidates demonstrating potential efficacy against COVID-19MP0420 and MP0423 are potential medicines with a...(Accesswire)

Novartis announces collaboration with Molecular Partners to develop two DARPin(R) therapies designed for potential use against COVID-19

- Novartis has been granted an option to in-license global rights of MP0420 and MP0423 - multi-targeted direct acting antiviral therapeutic candidates demonstrating potential efficacy against COVID-19 (Thomson Reuters ONE)

October 27, 2020
Molecular Diagnostics Market Rises at 7.1% CAGR and Hit US$ 13,873.6 Mn by 2025; Clinical and Pathology Labs to Show Higher Demand, says Fortune Business Insights

The rising incidence of infectious diseases is fueling demand in the global molecular diagnostics market. Fortune Business Insights (FBI) has published a report, titled "Molecular Diagnostics Market Size, Share and Global Trend by Product Type...(Globe Newswire)

REGENXBIO to Receive $80.0 Million Milestone Payment from Novartis AG

REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV(R) Technology Platform, today announced that it will receive a...(PR Newswire)

Novartis delivers solid Q3 performance with 11% core operating income growth, net sales in line with prior year, strong pipeline progression. Upgrades full year core operating income guidance.

- Q3 net sales from continuing operations1 were in line with prior year (cc2, +1% USD): - Growth drivers included Entresto USD 632 million (+45% cc), Zolgensma USD 291 million (+79% cc), Cosentyx USD 1 012 million (+7% cc), Kisqali USD 183...(Thomson Reuters ONE)

October 26, 2020
Novartis presents promising interim Phase II data of potential first-in-class oral therapy iptacopan (LNP023) in rare renal disease C3 glomerulopathy (C3G)

- C3 glomerulopathy (C3G) is a rare renal disease, affecting young patients with a poor prognosis and significant unmet need.1-3 - Iptacopan (LNP023) is a potential first-in-class, oral, potent and selective factor B inhibitor of the complement...(Thomson Reuters ONE)

October 22, 2020
[2020-2027] Conjunctivitis Treatment Market Worth USD 4.38 Billion at 3.7% CAGR; Management of Ocular Disorders to Augment Growth, says Fortune Business Insights(TM)

The global conjunctivitis treatment market size is set to gain traction from the rising technological advancements in the field of ophthalmology. Besides, the increasing discovery of new techniques of drug delivery would also impact the market...(Globe Newswire)

Elsevier Signs Collaboration to Develop Novel Prediction Tool to Reduce Drug Development Safety Risk

Elsevier, a global information analytics business specializing in science and health, today announced its collaboration with the pharmaceutical company Novartis to develop a safety margin risk assessment prediction tool, largely using PharmaPendium...(PR Newswire)

October 21, 2020
Vaccines Market to Advance Impressively, Exhibit a CAGR of 10.7% and Reach USD 104.87 Billion by 2027

The global vaccines market size is expected to reach USD 104.87 billion by 2027, exhibiting a CAGR of 10.7% during the forecast period. The ongoing clinical trials for COVID-19 vaccine will have a tremendous impact on the global market. (Globe Newswire)

October 20, 2020
Global Anti-Glaucoma Drugs Market: COVID-19 Impact And Analysis, Market Drivers, And Trends (Companies Covered: Allergen Plc, Novartis AG, Santen Pharmaceuticals Co, Ltd., Akorn, and Pfizer)

This has shifted resources from the antiglaucoma drugs market to the antiviral drug therapies market. The coronavirus outbreak has also caused shortage in the supply of glaucoma drugs worldwide. This is because of the disruption in the supply chain...(Globe Newswire)

Banking on the Next Blockbuster Drug

Pharmaceutical companies invest enormous amounts of time and money on the research and development of new drugs, typically years in the making and costing millions of dollars. Only occasionally is a new drug developed that's approved and generates...(PR Newswire)

October 16, 2020
Novartis receives positive CHMP opinion for Leqvio(R)* (inclisiran), a potential first-in-class siRNA for the treatment of high cholesterol

- If approved, inclisiran will be the first and only small interfering RNA (siRNA) in Europe for patients with hypercholesterolemia or mixed dyslipidemia1 - Cardiovascular disease (CVD) claims 3.9 million lives annually in Europe2, and 80% of...(Thomson Reuters ONE)

October 15, 2020
Eurecon: Pharma Trend Awards Best Pharmaceutical Company and Most Innovative Product 2020

The results of the ranking "Best Pharmaceutical Company in Germany 2020" are in. Novartis Pharma, Janssen-Cilag, GlaxoSmithKline, Amgen and Bristol-Myers Squibb have taken first to fifth place in the Pharma Trend Image & Innovation Award survey...(BusinessWire)

Next >

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.